SK Biopharmaceuticals Appoints Chey Yoon-chung as Strategy H

Chey Yoon-chung has been appointed as the head of the newly established strategy department at SK Biopharmaceuticals, effective January 1. In this strategic role, she will oversee mid- to long-term planning, portfolio management, and global expansion efforts, marking a significant shift for SK Group as they look to diversify beyond their semiconductor core driven by SK hynix’s successes. With a background in biology and experience in consulting, Chey’s leadership comes at a pivotal time as the company aims to strengthen its presence in the biopharmaceutical sector while posting record earnings from their epilepsy treatment product, cenobamate.

Her focus will shift towards identifying the next growth drivers for SK Biopharmaceuticals, reflecting the group's strategic pivot towards biotechnology. As SK Biopharmaceuticals has been thriving through strong US sales and looks to expand further, Chey’s leadership will be vital for enhancing global partnerships and exploring innovative modalities in drug development. This evolution signifies a potential increase in the company's autonomy within the biopharmaceutical landscape and a departure from a dependence on semiconductor revenues, positioning SK Biopharmaceuticals as a more diversified player in the tech-influenced healthcare market.